[HTML][HTML] Identification of microRNA-124-3p as a putative epigenetic signature of major depressive disorder

B Roy, M Dunbar, RC Shelton, Y Dwivedi - Neuropsychopharmacology, 2017 - nature.com
Major depressive disorder (MDD) is predicted to be the second leading cause of global
disease burden by 2030. A large number of MDD patients do not respond to the currently …

Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder

B Roy, M Dunbar, RC Shelton… - … : official publication of …, 2017 - pubmed.ncbi.nlm.nih.gov
Major depressive disorder (MDD) is predicted to be the second leading cause of global
disease burden by 2030. A large number of MDD patients do not respond to the currently …

Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.

B Roy, M Dunbar, RC Shelton… - … : Official Publication of the …, 2016 - europepmc.org
Major depressive disorder (MDD) is predicted to be the second leading cause of global
disease burden by 2030. A large number of MDD patients do not respond to the currently …

[HTML][HTML] Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder

B Roy, M Dunbar, RC Shelton… - …, 2017 - ncbi.nlm.nih.gov
Major depressive disorder (MDD) is predicted to be the second leading cause of global
disease burden by 2030. A large number of MDD patients do not respond to the currently …

[引用][C] Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder

B Roy, M Dunbar, RC Shelton, Y Dwivedi - Neuropsychopharmacology, 2016 - cir.nii.ac.jp
Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive
Disorder | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.

B Roy, M Dunbar, RC Shelton… - … : Official Publication of the …, 2016 - europepmc.org
Major depressive disorder (MDD) is predicted to be the second leading cause of global
disease burden by 2030. A large number of MDD patients do not respond to the currently …